CER Daily Newsfeed

ISPOR 2026 Daily Round-Ups: Insights from Day 2

(5/20, Joanne Walker, Katie McCool, Laura Dormer, The Evidence Base) reports “...Jon D Campbell (National Pharmaceutical Council) highlighted the distinction between pricing, spending, and value, outlining evidence suggesting that new drug launches are not the primary driver of overall US prescription medicine spending growth. Drawing on recent IQVIA analyses, Campbell discussed how savings associated with loss of exclusivity can offset spending increases from new therapies. He also examined trends showing that net medicine spending has remained a relatively stable proportion of overall US healthcare expenditure over time, while arguing that medicines continue to generate substantial societal value through improved outcomes and gains in life expectancy. Campbell stressed the importance of inflation-adjusted analyses, stating: ‘pricing is different from spending.’” Full

FDA Official Offers Examples of RWE Being Used to Secure Drug Approval

(5/19, Joanne S. Eglovitch, Regulatory Focus) reports “...[Motiur Rahman, a senior epidemiologist and policy advisor in the Office of Medical Policy at CDER,] said that interest in RWE has grown with improved access to big data and tools for analyzing this data. In addition, he said that research shows that observational studies can generate results similar to those of randomized controlled trials. FDA has been increasingly involved in the RWD/RWE space since the passage of the 21st Century Cures Act in 2016, which mandated that FDA establish a program for evaluating this data in regulatory decision-making.” Full

Video: Why Oncology Real-World Data Is Broken—and How Clinically Relevant Edit Checks Fix It

(5/20, Ryu Kariyawasam-Chavez, Sarah Spark, MHA, Pharmacy Times) “Pharmacy Times interviews Sarah Spark, MHA MBA, Director of Clinical Data Quality at Ontada, on how clinically relevant edit checks are improving the accuracy and reliability of oncology real-world data to better support clinical decision-making, research, and patient outcomes.” View Video

Industry Wants More White House Action To Raise Ex-US Drug Prices After MFN Deals

(5/19, Jessica Merrill, Pink Sheet) reports “...The US government’s Most Favored Nation drug pricing agreement could spur a race to the bottom on pricing or increase pressure to move to value-based pricing, experts said.” Subscription Required

Germany And France Join Forces To Counter MFN And Other Threats To European Pharma

(5/20, Francesca Bruce, Pink Sheet) reports “...Germany and France have signaled to Europe’s pharmaceutical industry that they are committed to securing its future by countering threats including foreign economic measures such as the US Most Favored Nation policies and competition from China.” Subscription Required